Other News

Real-World Study Confirms Benefit of XARELTO® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients

Head-to-head observational analysis showed XARELTO® as effective in treating cancer-associated thromboembolism (CAT) as apixaban Venous thromboembolism (VTE) is the second-leading cause of death in patients with cancer1 TITUSVILLE, N.J., Dec. 9, 2022 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing […]

EDWARDS LIFESCIENCES ANNOUNCES CEO SUCCESSION PLAN

IRVINE, Calif., Dec. 8, 2022 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW) today announced that following regular succession planning discussions with the Board of Directors, Edwards’ chairman and CEO, Michael A. Mussallem, who recently turned 70, has informed the Board of his decision to retire as CEO in connection with the company’s Annual Meeting […]

Provident Healthcare Partners Advises Southwest Cardiovascular Associates in its Partnership with Cardiovascular Associates of America

BOSTON and NEW YORK, Dec. 8, 2022 /PRNewswire/ — Provident Healthcare Partners (“Provident”), a leading healthcare investment banking firm, announced it has advised Southwest Cardiovascular Associates (“SWCVA” or “Company”) in its partnership with Cardiovascular Associates of America (“CVAUSA”), a portfolio company of Webster Equity Partners. SWCVA provides interventional and diagnostic cardiology services throughout its three-location footprint […]

Tenaya Therapeutics Appoints Amy Burroughs to Board of Directors

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) — Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the appointment of Amy Burroughs to its Board of Directors. […]

Primary endpoint met in the CLEAR Outcomes Trial of bempedoic acid showing statistically significant relative risk reduction in major adverse CV events

Successful topline results from the CLEAR Outcomes Trial demonstrate that bempedoic acid, marketed as NILEMDO®▼ in Europe, reduces the risk of serious cardiovascular (CV) events in patients with, or who are at, high risk for atherosclerotic cardiovascular disease (ASCVD) with elevated LDL-C levels1,2 The results position bempedoic acid as the […]

EDWARDS LIFESCIENCES OUTLINES GROWTH STRATEGY AT ANNUAL INVESTOR CONFERENCE

IRVINE, Calif., Dec. 8, 2022 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW) will discuss the company’s strategy for longer-term growth, provide an update on its technology pipeline and share its financial guidance1 today during its annual investor conference. Highlights of today’s conference include: Global market opportunity across 4 product groups projected to double to […]

AtriCure Wins 2022 NACD Diversity, Equity, & Inclusion Award

Recognizes Exemplary Board Practices Related to DE&I MASON, Ohio–(BUSINESS WIRE)–AtriCure Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced that it has been named a winner of the 2022 Diversity, Equity & Inclusion Award […]

CARMAT Successfully Raises a Total of €31.1 Million via the Issuance of 2,960,710 Shares

NOT FOR RELEASE, EITHER DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (Paris:ALCAR) (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative to people suffering from end-stage biventricular heart failure (the “Company”), […]